Compare IDXX & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | RVMD |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 40.3B |
| IPO Year | 1996 | 2020 |
| Metric | IDXX | RVMD |
|---|---|---|
| Price | $678.73 | $162.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | ★ $717.17 | $274.68 |
| AVG Volume (30 Days) | 577.0K | ★ 2.2M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 11.75 | N/A |
| Revenue | ★ $4,303,702,000.00 | N/A |
| Revenue This Year | $10.50 | N/A |
| Revenue Next Year | $8.88 | $233.69 |
| P/E Ratio | $58.72 | ★ N/A |
| Revenue Growth | ★ 10.42 | N/A |
| 52 Week Low | $500.61 | $71.15 |
| 52 Week High | $769.98 | $224.31 |
| Indicator | IDXX | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 36.14 |
| Support Level | $530.28 | $137.82 |
| Resistance Level | $713.74 | $166.50 |
| Average True Range (ATR) | 22.25 | 10.49 |
| MACD | -3.14 | -2.76 |
| Stochastic Oscillator | 43.94 | 6.78 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.